Clinical Trials
61 trialsNCT04126070 2026-05-27
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00544830 2026-05-15
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03361735 2026-04-09
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01194271 2024-06-06
Neoadjuvant Ipilimumab in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03572387 2024-04-30
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01377389 2023-09-29
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01326312 2023-06-22
GTx758
GTx
Phase 2 Terminated
NCT02058706 2023-05-10
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02770391 2022-06-21
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02508636 2021-10-12
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01338987 2021-03-18
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02064582 2020-10-12
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02168062 2020-07-23
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03093272 2020-04-09
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT00937768 2019-12-27
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Mayo Clinic
Phase 2 Terminated
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT00254397 2019-10-16
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02057939 2019-06-26
STREAM
Duke University
Phase 2 Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT00223665 2018-08-07
IAS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT02083185 2018-05-09
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
Takeda
Phase 2 Completed
NCT00860158 2018-03-14
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01343368 2017-12-05
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT01023061 2017-06-06
RAD1
University of Washington
Phase 2 Completed
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT02212197 2017-04-25
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Camurus AB
Phase 2 Completed
NCT01750398 2016-12-05
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01076335 2016-09-19
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed